Characterization of retinal function and structure in the MPTP murine model of Parkinson’s disease

Katie K.N. Tran, Vickie H.Y. Wong, Jeremiah K.H. Lim, Ali Shahandeh, Anh Hoang, David I. Finkelstein, Bang V. Bui, Christine T.O. Nguyen

Research output: Contribution to journalArticlepeer-review

Abstract

In addition to well characterized motor symptoms, visual disturbances are increasingly recognized as an early manifestation in Parkinson’s disease (PD). A better understanding of the mechanisms underlying these changes would facilitate the development of vision tests which can be used as preclinical biomarkers to support the development of novel therapeutics for PD. This study aims to characterize the retinal phenotype of a mouse model of dopaminergic dysfunction and to examine whether these changes are reversible with levodopa treatment. We use a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD to characterize the neurotoxic effects of MPTP on in vivo retinal function (electroretinography, ERG), retinal structure (optical coherence tomography, OCT) and retinal dopaminergic cell number (tyrosine hydroxylase immunohistochemistry, IHC) at two time points (21 and 45 days) post MPTP model induction. We also investigate the effect of levodopa (L-DOPA) as a proof-of-principle chronic intervention against MPTP-induced changes in the retina. We show that MPTP decreases dopaminergic amacrine cell number (9%, p < 0.05) and that a component of the ERG that involves these cells, in particular oscillatory potential (OP) peak timing, was significantly delayed at Day 45 (7–13%, p < 0.01). This functional deficit was paralleled by outer plexiform layer (OPL) thinning (p < 0.05). L-DOPA treatment ameliorated oscillatory potential deficits (7–13%, p < 0.001) in MPTP animals. Our data suggest that the MPTP toxin slows the timing of inner retinal feedback circuits related to retinal dopaminergic pathways which mirrors findings from humans with PD. It also indicates that the MPTP model causes structural thinning of the outer retinal layer on OCT imaging that is not ameliorated with L-DOPA treatment. Together, these non-invasive measures serve as effective biomarkers for PD diagnosis as well as for quantifying the effect of therapy.

Original languageEnglish
Article number7610
Number of pages11
JournalScientific Reports
Volume12
DOIs
Publication statusPublished - Dec 2022

Keywords

  • Parkinson’s Disease
  • retinal function
  • Murine
  • MPTP murine model
  • 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)
  • L-DOPA

Fingerprint

Dive into the research topics of 'Characterization of retinal function and structure in the MPTP murine model of Parkinson’s disease'. Together they form a unique fingerprint.

Cite this